184 filings
Page 2 of 10
CORRESP
wdztwb69
7 Jul 23
Correspondence with SEC
12:00am
UPLOAD
503l7pf4cc7zqemo
6 Jul 23
Letter from SEC
12:00am
F-3
xe001cqp
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
rubo 3g2zvm0acoxzc
28 Jun 23
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
8:30am
6-K
uee 1j7qk2sq
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am
6-K
t22dcg8p
11 May 23
Current report (foreign)
8:00am
6-K
rszhudjep8br
27 Apr 23
Current report (foreign)
4:01pm
6-K
5iyv54vlb4fkg51m4
13 Apr 23
Current report (foreign)
4:01pm
424B5
jcfz e7teorsks7yom2
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
czgwssn65 7i
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
ft4ccfyb40
5 Apr 23
Current report (foreign)
4:01pm
6-K
qeo a4612612883zmp
4 Apr 23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4:50pm
6-K
e929dss48b
22 Mar 23
InflaRx Reports Full Year 2022 Financial and Operating Results
7:37am
6-K
4ucrzkraw
5 Jan 23
Current report (foreign)
8:00am
6-K
9qlgm0ee0amzcoj
21 Dec 22
Current report (foreign)
7:45am
6-K
zp14 iufosco
9 Nov 22
Current report (foreign)
7:53am
6-K
6x34ckbn
9 Nov 22
Current report (foreign)
7:52am
6-K
6fpy3 5m2kh
29 Sep 22
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
8:00am
6-K
dr0reo
8 Sep 22
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
8:00am